29 Jul 2011

Decision in the case of Robert Kendrick


London, England, 29 Jul 2011 - The International Tennis Federation announced today that Robert Kendrick has been found to have committed a Doping Offence under Article C.1 of the Tennis Anti-Doping Programme (presence of a Prohibited Substance in player’s sample).

Mr Kendrick, a 31-year-old tennis player from the United States, provided a sample on 22 May 2011 at the French Open held in Paris, France. That sample was sent to the WADA-accredited laboratory in Montreal, Canada for analysis, and was found to contain methylhexaneamine, a stimulant. Methylhexaneamine is a Prohibited Substance under section S6 of the 2011 WADA List of Prohibited Substances and Prohibited Methods, and is therefore also prohibited under the Tennis Anti-Doping Programme. Mr Kendrick was therefore charged with an anti-doping rule violation under Article C.1 of the Programme.

Mr Kendrick asserted that the methylhexaneamine had got into his system through his ingestion of a capsule of Zija XM3, which he took to combat jetlag. He denied any intent to enhance his performance as a result of taking this substance.

The ITF did not dispute Mr Kendrick’s account of the circumstances surrounding his ingestion of methylhexaneamine, or that he did not intend to enhance his performance. Under the Tennis Anti-Doping Programme, however, it is a player’s strict personal duty to ensure that no Prohibited Substance enters his body, whether as a prescription medication or otherwise, unless he holds a valid therapeutic use exemption (TUE) for such substance. Mr Kendrick did not hold a valid TUE.

A tribunal therefore confirmed Mr Kendrick’s commission of a Doping Offence under Article C.1 of the Tennis Anti-Doping Programme, and determined that he should be suspended from participation for a period of 12 months, commencing as from 22 May 2011 and so ending at midnight on 21 May 2012. The tribunal also determined that Mr Kendrick’s results at the 2011 French Open should be disqualified, with resulting forfeiture of the ranking points and prize money that he won at those events.

The Tennis Anti-Doping Programme is a comprehensive and internationally recognised drug-testing programme that applies to all players competing at tournaments sanctioned by the ITF, ATP World Tour, and WTA. Players are tested for substances prohibited by the World Anti-Doping Agency and, upon a finding that a Doping Offence has been committed, sanctions are imposed in accordance with the requirements of the World Anti-Doping Code. More background information on the Programme, sanctions, tennis statistics and related information can be found at www.itftennis.com/antidoping.